NVDA's Bounce Is Dead. The Daily Short Is Accelerating.NVIDIA CorporationNASDAQ:NVDAvirDeStateraNVDA's Bounce Is Dead. The Daily Short Is Accelerating. NVDA never recovered the 199.89 line it briefly reclaimed, and it is now trading at 196.95 with the daily selling picking up speed. The two-day bounce is over - yesterday's rejection under 199 handed control back to the sellers, and there is no buying underneath to slow it. The volume behind the recovery has completely evaporated, sitting at the very bottom of its range. The path back to the April floor at 191.23 is open, with 194.41 the only real shelf in between. Resistance: 198.47 - the level lost overnight Key resistance: 199.89 - the reclaimed-then-lost line, now firm resistance Current price: 196.95 Support: 194.41 - the only shelf above the floor Key support: 191.23 - the April floor Structural floor: 189.80 - the June sweep low Two paths from here: The daily short runs to the floor. The move is accelerating, the swing low is swept, and the short signal is loaded at PARTIAL with the SYNTH gate active - the machinery is engaged, not just building. A loss of 194.41 puts 191.23 in play directly, and a break of that opens the 189.80 sweep low. Vol Elev at the 0th percentile says there are no buyers to defend on the way down. The floor holds a third time. 191.23 has held twice as the structural floor this cycle, and the hourly bull print, though orphaned above current price, still carries a clean read at CQI 66. If buyers step in at 194.41 or the floor, a reclaim of 198.47 puts the bounce back on. But this needs volume that simply is not there, and the daily has already re-committed to the downside. The cross-timeframe split resolved the way these usually do - toward the timeframe that never blinked. The daily bear call never wavered while the hourly bounced, and now price has followed the daily down. The hourly bull print is still technically on the board but abandoned by price and volume both. 191.23 is the number that matters. Built with SYNTHESIS v3.3 | SOM / ACE / IMP / SYNTHESIS Study, not financial advice.